Key facts
- 4Moving Biotech’s last known valuation is $20.8M (Apr 2021).
- It has raised $16.5M; the latest was Later Stage VC ($14.1M) in Feb 2026.
- Notable investors include Bpifrance, France 2030, 4P-Pharma, SATT Lutech.
- Status: Privately Held (backing).
Investors
4- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for 4Moving Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for 4Moving Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 4Moving Biotech
Operator of a biopharmaceutical research firm intended to develop therapies for osteoarthritis patients. The company uses GLP-1 analogs to target low-grade inflammation and integrates advanced artificial intelligence with real-world data to accelerate clinical trial design, enabling the restoration of mobility and improving quality of life.
- Sector
- Healthcare
- HQ
- Lille, France
- Founded
- 2020
- Employees
- 8
- Website
- 4movingbiotech.com/
- Ownership
- Privately Held (backing)
4Moving Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 4Moving Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 4Moving Biotech in its N-PORT filings yet. We sweep new filings monthly.